Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219814 | 1.00 | LMNA (0.52) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738573 | 1.00 | LMNA (0.52) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738571 | 0.90 | LMNA (0.51) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216521 | 0.90 | LMNA (0.51) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216522 | 0.90 | LMNA (0.51) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL253498 | 0.89 | LMNA (0.52) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738570 | 0.89 | LMNA (0.52) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL253497 | 0.89 | LMNA (0.52) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL219694 | 0.88 | LMNA (0.57) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL218604 | 0.88 | LMNA (0.57) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-1685150-A2 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005047303-A2 | NOVEL 17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | HSD17B11, HSD17B1, HSD17B3 | LMNA 2693/4885HSD17B1 2/4885MAPT 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.